Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

Phillips, E.J., Sukasem, C., Whirl-Carrillo, M., Müller, D.J., Dunnenberger, H.M., Chantratita, W., Goldspiel, B., Chen, Y-T, Carleton, B.C., George, A.L., Mushiroda, T., Klein, T., Gammal, R.S. and Pirmohamed, M. (2018) Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clinical Pharmacology & Therapeutics, 103 (4). pp. 574-581.

Link to Published Version: https://doi.org/10.1002/cpt.1004
*Subscription may be required

Abstract

The variant allele HLA‐B*15:02 is strongly associated with greater risk of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA‐A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.

Item Type: Journal Article
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Publisher: Nature Publishing Group
Copyright: © 2018 American Society for Clinical Pharmacology and Therapeutics
URI: http://researchrepository.murdoch.edu.au/id/eprint/41462
Item Control Page Item Control Page